Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)

Detalhes bibliográficos
Autor(a) principal: Quintella, Cristina M.
Data de Publicação: 2020
Outros Autores: Silva, Lucilia Abreu Cabral e, Quintella, Heitor da Mata, Silva, Gustavo Henrique Ramos, Silva, Sávio Carlos Rodrigues da, Uchoa, Sílvia Beatriz Beger, Mata, Pedro Miguel de Assis Lopes Tavares da
Tipo de documento: Artigo
Idioma: por
Título da fonte: Cadernos de Prospecção (Online)
Texto Completo: https://periodicos.ufba.br/index.php/nit/article/view/36815
Resumo: This work analyzes the drugs used for patients with COVID-19 which are undergoing clinical trials and that go well beyond chloroquine. The data were obtained from the World Health Organization's International Clinical Trials Registration Platform. Geodistribution shows concentration in China, and only 5% of transnational partnerships. Clinical tests are concentrated in intermediate phases II and III. The classes of drugs go far beyond antimalarials, which have become popularly known, also comprising antivirals, anti-inflammatories, antibiotics, anticoagulants, antibodies, antifibrotics, antitumor agents, calcium channel blockers, corticosteroids, immunomodulators, immunosuppressants, enzyme inhibitors, mucolytics, vasoconstrictors and vasodilators, vitamins and mineral salts. The most tested antivirals are Ritonavir, Remdesivir, Lopinavir, Favipiravir and Arbidol, as well as their associations. Several tests combine antimalarials, antivirals and immunomodulators, the most studied being Favipiravir and Lopinavir associated with Ritonavir, Methylprednisolone, Remdesivir, Tocilizumab, Chloroquine and Hydroxychloroquine.
id UFBA-6_90337d94cba1480026ac97b88ccef756
oai_identifier_str oai:ojs.periodicos.ufba.br:article/36815
network_acronym_str UFBA-6
network_name_str Cadernos de Prospecção (Online)
repository_id_str
spelling Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)Fármacos para COVID-19: muito além da cloroquina (testes clínicos para o coronavírus SARS-CoV-2)níveis de maturidade tecnológicaTRLvíruspandemiasTerapiasAvaliação de tecnologia.Technological Maturity Levels (TRL)VirusesPandemicsTherapiesTechnology Assessment.This work analyzes the drugs used for patients with COVID-19 which are undergoing clinical trials and that go well beyond chloroquine. The data were obtained from the World Health Organization's International Clinical Trials Registration Platform. Geodistribution shows concentration in China, and only 5% of transnational partnerships. Clinical tests are concentrated in intermediate phases II and III. The classes of drugs go far beyond antimalarials, which have become popularly known, also comprising antivirals, anti-inflammatories, antibiotics, anticoagulants, antibodies, antifibrotics, antitumor agents, calcium channel blockers, corticosteroids, immunomodulators, immunosuppressants, enzyme inhibitors, mucolytics, vasoconstrictors and vasodilators, vitamins and mineral salts. The most tested antivirals are Ritonavir, Remdesivir, Lopinavir, Favipiravir and Arbidol, as well as their associations. Several tests combine antimalarials, antivirals and immunomodulators, the most studied being Favipiravir and Lopinavir associated with Ritonavir, Methylprednisolone, Remdesivir, Tocilizumab, Chloroquine and Hydroxychloroquine.Este trabalho analisa os fármacos utilizados para pacientes com COVID-19, que estão em fase de testes clínicos e que vão muito além da cloroquina. Os dados foram obtidos na Plataforma Internacional de Registro de Ensaios Clínicos da Organização Mundial de Saúde (OMS). A geodistribuição mostra a concentração desses fármacos na China, e apenas 5% de parcerias transnacionais. Os testes clínicos se concentram nas fases intermediárias II e III. As classes de fármacos vão além dos antimaláricos, que têm se tornado popularmente conhecidos, compreendendo também antivirais, anti-inflamatórios, antibióticos, anticoagulantes, anticorpos, antifibróticos, antitumorais, bloqueadores de canais de cálcio, corticoides, imunomoduladores, imunossupressores, inibidores de enzimas, mucolíticos, vasoconstritores e vasodilatadores, vitaminas e sais minerais. Os antivirais mais testados são Ritonavir, Remdesivir, Lopinavir, Favipiravir e Arbidol, assim como suas associações. Diversos testes combinam antimaláricos, antivirais e imunomoduladores, sendo os mais estudados Favipiravir e Lopinavir, associados com Ritonavir, Metilprednisolona, Remdesivir, Tocilizumabe, Cloroquina e Hidroxicloroquina.Universidade Federal da Bahia2020-05-29info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://periodicos.ufba.br/index.php/nit/article/view/3681510.9771/cp.v13i3.36815Cadernos de Prospecção; Vol. 13 No. 3 (2020); 599Cadernos de Prospecção; v. 13 n. 3 (2020); 5992317-00261983-1358reponame:Cadernos de Prospecção (Online)instname:Universidade Federal da Bahia (UFBA)instacron:UFBAporhttps://periodicos.ufba.br/index.php/nit/article/view/36815/21127Copyright (c) 2020 Cadernos de Prospecçãohttps://creativecommons.org/licenses/by-nc/4.0info:eu-repo/semantics/openAccessQuintella, Cristina M.Silva, Lucilia Abreu Cabral eQuintella, Heitor da MataSilva, Gustavo Henrique RamosSilva, Sávio Carlos Rodrigues daUchoa, Sílvia Beatriz BegerMata, Pedro Miguel de Assis Lopes Tavares da2020-05-29T17:35:10Zoai:ojs.periodicos.ufba.br:article/36815Revistahttps://periodicos.ufba.br/index.php/nitPUBhttps://periodicos.ufba.br/index.php/nit/oaicadernosdeprospeccao@gmail.com || maliceribeiro@yahoo.com.br || cadernosdeprospeccao@gmail.com || saionaraluna@gmail.com2317-00261983-1358opendoar:2020-05-29T17:35:10Cadernos de Prospecção (Online) - Universidade Federal da Bahia (UFBA)false
dc.title.none.fl_str_mv Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
Fármacos para COVID-19: muito além da cloroquina (testes clínicos para o coronavírus SARS-CoV-2)
title Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
spellingShingle Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
Quintella, Cristina M.
níveis de maturidade tecnológica
TRL
vírus
pandemias
Terapias
Avaliação de tecnologia.
Technological Maturity Levels (TRL)
Viruses
Pandemics
Therapies
Technology Assessment.
title_short Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
title_full Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
title_fullStr Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
title_full_unstemmed Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
title_sort Drugs for COVID-19: far beyond chloroquine (clinical trials for SARS-CoV-2 coronavirus)
author Quintella, Cristina M.
author_facet Quintella, Cristina M.
Silva, Lucilia Abreu Cabral e
Quintella, Heitor da Mata
Silva, Gustavo Henrique Ramos
Silva, Sávio Carlos Rodrigues da
Uchoa, Sílvia Beatriz Beger
Mata, Pedro Miguel de Assis Lopes Tavares da
author_role author
author2 Silva, Lucilia Abreu Cabral e
Quintella, Heitor da Mata
Silva, Gustavo Henrique Ramos
Silva, Sávio Carlos Rodrigues da
Uchoa, Sílvia Beatriz Beger
Mata, Pedro Miguel de Assis Lopes Tavares da
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Quintella, Cristina M.
Silva, Lucilia Abreu Cabral e
Quintella, Heitor da Mata
Silva, Gustavo Henrique Ramos
Silva, Sávio Carlos Rodrigues da
Uchoa, Sílvia Beatriz Beger
Mata, Pedro Miguel de Assis Lopes Tavares da
dc.subject.por.fl_str_mv níveis de maturidade tecnológica
TRL
vírus
pandemias
Terapias
Avaliação de tecnologia.
Technological Maturity Levels (TRL)
Viruses
Pandemics
Therapies
Technology Assessment.
topic níveis de maturidade tecnológica
TRL
vírus
pandemias
Terapias
Avaliação de tecnologia.
Technological Maturity Levels (TRL)
Viruses
Pandemics
Therapies
Technology Assessment.
description This work analyzes the drugs used for patients with COVID-19 which are undergoing clinical trials and that go well beyond chloroquine. The data were obtained from the World Health Organization's International Clinical Trials Registration Platform. Geodistribution shows concentration in China, and only 5% of transnational partnerships. Clinical tests are concentrated in intermediate phases II and III. The classes of drugs go far beyond antimalarials, which have become popularly known, also comprising antivirals, anti-inflammatories, antibiotics, anticoagulants, antibodies, antifibrotics, antitumor agents, calcium channel blockers, corticosteroids, immunomodulators, immunosuppressants, enzyme inhibitors, mucolytics, vasoconstrictors and vasodilators, vitamins and mineral salts. The most tested antivirals are Ritonavir, Remdesivir, Lopinavir, Favipiravir and Arbidol, as well as their associations. Several tests combine antimalarials, antivirals and immunomodulators, the most studied being Favipiravir and Lopinavir associated with Ritonavir, Methylprednisolone, Remdesivir, Tocilizumab, Chloroquine and Hydroxychloroquine.
publishDate 2020
dc.date.none.fl_str_mv 2020-05-29
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://periodicos.ufba.br/index.php/nit/article/view/36815
10.9771/cp.v13i3.36815
url https://periodicos.ufba.br/index.php/nit/article/view/36815
identifier_str_mv 10.9771/cp.v13i3.36815
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://periodicos.ufba.br/index.php/nit/article/view/36815/21127
dc.rights.driver.fl_str_mv Copyright (c) 2020 Cadernos de Prospecção
https://creativecommons.org/licenses/by-nc/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 Cadernos de Prospecção
https://creativecommons.org/licenses/by-nc/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal da Bahia
publisher.none.fl_str_mv Universidade Federal da Bahia
dc.source.none.fl_str_mv Cadernos de Prospecção; Vol. 13 No. 3 (2020); 599
Cadernos de Prospecção; v. 13 n. 3 (2020); 599
2317-0026
1983-1358
reponame:Cadernos de Prospecção (Online)
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Cadernos de Prospecção (Online)
collection Cadernos de Prospecção (Online)
repository.name.fl_str_mv Cadernos de Prospecção (Online) - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv cadernosdeprospeccao@gmail.com || maliceribeiro@yahoo.com.br || cadernosdeprospeccao@gmail.com || saionaraluna@gmail.com
_version_ 1799319847873544192